15:41:22 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
DanCann Pharma grundades 2018 och är ett danskt läkemedelsbioteknikbolag som drivs av cannabinoider. DanCann Pharma fokuserar på att upptäcka, utveckla, tillverka och kommersialisera nya cannabinoida läkemedel inom ett brett spektrum av sjukdomsområden. Bolaget tillverkar och distribuerar receptbelagda läkemedel och receptfria läkemedel (OTC), främst fokuserade på smärtpatienter med alternativa behov och hantering av sin sjukdom, täckta av det danska pilotprogrammet för medicinsk cannabis.

Kalender

2022-04-07 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-07-23 Extra Bolagsstämma 2021
2021-05-28 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning DANCAN 0.00 DKK
2021-04-28 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2021-03-09 14:00:00

COPENHAGEN, Denmark, 9 March 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") is pleased to announce the employment of Jens Markussen. Jens Markussen has been appointed as Head of Production at DanCann Pharma A/S.

Jens Markussen joins the DanCann Pharma production team as the company's Head of Production. Jens Markussen will oversee all production and post-harvest activities of the BIOTECH PHARM1. This includes standardization of operations, compliance, applications, and approvals related to products produced at DanCann Pharma's BIOTECH PHARM1.

Jens Markussen has already a proven track record within the medical cannabis industry as he is former Head of Production at Spectrum Therapeutics Denmark A/S, part of the Canopy Growth Corp. (NASDAQ: CGC) group. During his time at Spectrum Therapeutics Denmark, Jens has overseen the construction and approval of a 2,500 m2 GMP-facility for harvesting, drying, and packaging of dried cannabis. Before his time at Spectrum Therapeutics Denmark, Jens worked as Production Manager at Fertin Pharma A/S. In addition, Jens has proven track record in process and LEAN optimization within the pharma- and medical cannabis industry.

Jens explains: "From my very first meeting with the DanCann Pharma team, I was determined to join and be part of the company. My previous proven track-record, expertise and knowledge with Medical Cannabis production will aid DanCann Pharma towards the important, forthcoming milestone - the GMP approval of BIOTECH PHARM1 later this year. I am very excited to work with the DanCann Pharma team who share a such strong passion for improving quality of life for patients with challenges. I look forward to the exciting months to come."

Morten Martinsen, COO at DanCann Pharma elaborates: "Jens' know-how and experience with Medical cannabis under Danish and European regulations are exceptional and one-of-a-kind in this novel industry - these will aid DanCann Pharma's production activities- and ease application and approval processes with the Danish Medical Agency.

We are very excited about the appointment of Jens Markussen as Head of Production. It is a significant and important step for DanCann pharma and towards the forthcoming GMP-approval of BIOTECH PHARM1.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com